Sydnexis
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
445 Marine View Ave Ste 295, Del Mar, Ca...Phone Number
(858) 925-6172Website
www.sydnexis.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Sydnexis
Sydnexis is a San Diego based clinical stage pharmaceutical company currently in the middle of a pivotal Phase 3 study, focused on the development of a novel proprietary formulation of low dose atropine for the treatment of myopia.Explore more
Popular SearchesSydnexis IncSydnexisSIC Code 28,283NAICS Code 32,325Show moreSydnexis Org Chart
EH
Vice President, Market Access and Reimburseme...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sydnexis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Sydnexis launches new products
Click to see if Sydnexis had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if Sydnexis is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Sydnexis has new funding data
Earning: See what the market has to say on Sydnexis recently announced quarterly report
Check if Sydnexis has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Sydnexis
Sydnexis, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Sydnexis
Find more new buyers
Compare Similar Companies to Sydnexis
Compare insights from companies similar to Sydnexis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Sydnexis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sydnexis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sydnexis.
Sydnexis financials insights
Gather financial insights about Sydnexis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$5.5M
2021
Series B
$45M
Sydnexis Tech Stack
A closer look at the technologies used by Sydnexis
See more technologies
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Person-Based
Person-Based
Sydnexis News & Media
Sydnexis Announces Positive CHMP Opinion in Europe for SYD-101 for Slowing the Progression of Pediatric Myopia
DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc. (www.sydnexis.com), a pre-commercial stage biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion for its proprietary low-dose atropine formulation, SYD-101, for slowing the progression of pediatric myopia. Santen SA licensed the rights from Sydnexis to commercialize SYD-101 under the brand name Ryjunea® in the regions of Europe, MiSydnexis Announces FDA Acceptance of New Drug Application for SYD-101 for the Treatment of Progression of Pediatric Myopia
DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc. (www.sydnexis.com), a pre-commercial stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for SYD-101 and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 23, 2025. If approved, SYD-101 would be the first and only pharmaceutical option for the treatment of progression of pediatric myopia in the United States. “The FDA acceptPerry J. Sternberg Joins Sydnexis as Chief Executive Officer
DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., (www.sydnexis.com) a pre-commercial stage biopharmaceutical company focused on the treatment of progression of pediatric myopia, is excited to announce the appointment of Perry J. Sternberg as Chief Executive Officer and as a member of the Board of Directors. An accomplished pharma/biotech executive with over 30 years in the industry and 15 years in eye care, Perry will provide invaluable leadership experience to help guide Sydnexis’ strategic dSydnexis Welcomes Nick Ruth as Chief Commercial Officer
SAN DIEGO, CALIFORNIA, USA, August 29, 2023 /EINPresswire.com/ -- Sydnexis, Inc., ( www.sydnexis.com ) a clinical stage biopharmaceutical company focused on the treatment of progressive myopia in children and minimizing the risk of associated co- …
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sydnexis
Sign Up For FreeTo access detailed company insights
Sydnexis is a San Diego based clinical stage pharmaceutical company currently in the middle of a pivotal Phase 3 study, focused on the development of a novel proprietary formulation of low dose atropine for the treatment of myopia.... Read More
